Leerink Partnrs Issues Positive Estimate for Insmed Earnings

Insmed, Inc. (NASDAQ:INSM) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share estimates for shares of Insmed in a research note issued to investors on Monday, September 1st. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will post earnings of ($5.51) per share for the year, up from their previous estimate of ($5.55). The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. Leerink Partnrs also issued estimates for Insmed’s Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($1.08) EPS, Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($4.11) EPS and FY2027 earnings at ($2.51) EPS.

A number of other equities research analysts have also recently issued reports on INSM. Jefferies Financial Group upped their price objective on Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Citigroup upgraded Insmed to a “buy” rating in a research note on Tuesday, June 10th. HC Wainwright upped their price objective on Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Wells Fargo & Company upped their price objective on Insmed from $140.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Bank of America upped their price objective on Insmed from $94.00 to $109.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.79.

Insmed Trading Up 1.8%

Shares of Insmed stock opened at $145.10 on Thursday. Insmed has a 12-month low of $60.40 and a 12-month high of $146.84. The stock has a market cap of $30.67 billion, a P/E ratio of -25.41 and a beta of 0.97. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $114.64 and its 200-day moving average is $89.66.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same quarter in the prior year, the company earned ($1.94) EPS. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. M&T Bank Corp grew its holdings in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 147 shares in the last quarter. Snowden Capital Advisors LLC grew its holdings in Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 158 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Insmed by 24.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 186 shares in the last quarter. ORG Partners LLC grew its holdings in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares in the last quarter. Finally, Cullen Frost Bankers Inc. grew its holdings in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Michael Alexander Smith sold 24,272 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the sale, the insider owned 54,902 shares in the company, valued at approximately $7,899,848.78. This represents a 30.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Roger Adsett sold 25,000 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer owned 105,637 shares in the company, valued at approximately $13,477,168.46. This trade represents a 19.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 535,320 shares of company stock worth $54,581,793 in the last quarter. Company insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.